These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 18757091)

  • 1. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):817-21. PubMed ID: 18757091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction.
    Hamill V; Ford I; Fox K; Böhm M; Borer JS; Ferrari R; Komajda M; Steg PG; Tavazzi L; Tendera M; Swedberg K
    Am J Med; 2015 Oct; 128(10):1102-1108.e6. PubMed ID: 26044936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.
    ; Ferrari R; Ford I; Fox K; Steg PG; Tendera M
    Cardiology; 2008; 110(4):271-82. PubMed ID: 18595216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Parodi G; Bellandi B; Valenti R; Memisha G; Giuliani G; Velluzzi S; Migliorini A; Carrabba N; Antoniucci D
    Atherosclerosis; 2010 Jul; 211(1):255-9. PubMed ID: 20226462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
    Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate in coronary syndromes and heart failure.
    Orso F; Baldasseroni S; Maggioni AP
    Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The resting heart rate].
    Bemelmans RH; Visseren FL
    Ned Tijdschr Geneeskd; 2014; 158():A6931. PubMed ID: 24666528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.